| Health End-Point |
Low |
Central |
High |
Unit (2010) per case
|
| Sleep disturbance |
480 |
1,240 |
1,570 |
Euro/year
|
| Hypertension |
880 |
950 |
1,110 |
Euro/year
|
| Acute myocardial infarction |
4,675 |
86,200 |
436,200 |
Euro
|
| Increased mortality risk (infants) |
1,120,000 |
4,485,731 |
11,200,000 |
Euro
|
| New cases of chronic bronchitis |
43,000 |
66,000 |
100,000 |
Euro
|
| Severe COPD |
70,000 |
120,000 |
260,000 |
Euro
|
| Increased mortality risk - Value Of Life Years |
89,715 |
89,715 |
89,715 |
Euro
|
| Increased mortality risk - VSLacute |
1,121,433 |
1,121,433 |
5,607,164 |
Euro
|
| Increased mortality risk - VPFacute |
1,120,000 |
1,650,000 |
5,600,000 |
Euro
|
| Life expectancy reduction - Value of Life Years chronic |
37,500 |
59,810 |
213,820 |
Euro
|
| Respiratory hospital admissions |
2,990 |
2,990 |
8,074 |
Euro
|
| Cardiac hospital admissions |
2,990 |
2,990 |
8,074 |
Euro
|
| Work loss days (WLD) |
441 |
441 |
441 |
Euro
|
| Restricted activity days (RADs) |
194 |
194 |
194 |
Euro
|
| Minor restricted activity days (MRAD) |
57 |
57 |
57 |
Euro
|
| Lower respiratory symptoms |
57 |
57 |
57 |
Euro
|
| LRS excluding cough |
57 |
57 |
57 |
Euro
|
| Cough days |
57 |
57 |
57 |
Euro
|
| Medication use / bronchodilator use |
74 |
80 |
96 |
Euro
|
| Lung cancer |
69,080 |
719,212 |
4,187,879 |
Euro
|
| Leukaemia |
2,045,493 |
3,974,358 |
7,114,370 |
Euro
|
| Neuro-development disorders |
4,486 |
14,952 |
32,895 |
Euro
|
| Skin cancer |
10,953 |
13,906 |
26,765 |
Euro
|
| Osteoporosis |
2,990 |
5,682 |
8,074 |
Euro
|
| Renal dysfunction |
22,788 |
30,406 |
40,977 |
Euro
|
| Anaemia |
748 |
748 |
748 |
Euro
|